Bleomycin Chemotherapy

Bleomycin, a chemotherapy agent, has been a cornerstone in cancer treatment since its discovery in the 1960s. It operates by disrupting DNA replication, leading to cancer cell death. Particularly effective against testicular cancer, Hodgkin's lymphoma, and squamous cell carcinomas, its use extends to various malignancies. However, its efficacy is tempered by significant pulmonary toxicity, a unique challenge in its administration. Research efforts have focused on strategies to mitigate this side effect, such as dose adjustments and pulmonary function monitoring. Additionally, studies explore combining bleomycin with other drugs to enhance its anticancer effects while minimizing pulmonary damage. As research advances, optimizing bleomycin's therapeutic potential remains crucial in improving cancer outcomes while managing its adverse effects.